Payers have promised a fight over the price of PCSK9 drugs, a new class of cholesterol fighters. Drugmakers in the field--including frontrunners Amgen and Sanofi--prepared for that fight. And now, analysts think they've defined the battle lines.
Regeneron posted another round of clinical successes from its sweeping Phase III rheumatoid arthritis program, plotting to submit its Sanofi-partnered antibody for regulatory scrutiny this year.
Regeneron has advanced dupilumab, regarded by many as the company's next big innovation, into a Phase III asthma study, rolling toward an FDA submission behind its lead eczema program.
Regeneron Pharmaceuticals is lobbying for the exome sequencing database it is building with Geisinger Health System to become the linchpin of President Obama's Precision Medicine program.
Since Regeneron signed on with Geisinger Health System early last year, the biotech has amassed sequencing data on dozens of promising genetic targets for a slate of ailments, including some common ones like high cholesterol. One new discovery could lay the foundation for a new drug to treat a cause of severe obesity in children, the company tells Reuters.
While many Big Pharma companies continued to whittle away at their multibillion-dollar R&D operations over the past year, laying off thousands of researchers, a group of midcap biotechs is helping to pick up the slack, according to a new report from GlobalData. And some big spenders like Regeneron and Alnylam led the way, helping drive up the group's total research spending by $2 billion, or 26%, to $9.7 billion.
As tensions begin to ease between the U.S. and Cuba, partnership opportunities may arise for stateside drugmakers--and Regeneron CEO Len Schleifer is heading down to the country to help get the ball rolling.
Who says bigger is better? According to a new report, mid-cap biotech companies are doing pretty well for themselves, thank you very much.
What's better than a new drug launch? A launch destined for greatness, of course. For sales and marketing teams, that's about as much job security as you can get.
Regeneron chief Len Schleifer has topped the ranks of biopharma's highest-paid skippers for the past couple of years now, and though his salary may be rising still, being CEO doesn't quite come with all the perks it used to.